DermaSensor complements medical professionals with new handheld non-invasive skin cancer detection tool
Sydney, Australia, 16th-18th October 2020: DermaSensor, the medical device company that enables healthcare professionals to efficiently check for skin cancer, will demonstrate its revolutionary skin cancer detection technology at the General Practice Conference & Exhibition in Sydney.
The General Practice Conference & Exhibition (GPCE) in Sydney is New South Wales’ leading CPD event for primary care and one of the most important CPD events on the general practice calendar. Hundreds of healthcare professionals meet to update knowledge, earn CPD points and see the latest primary care innovations.
The GPCE arms attendees with cross-disciplinary skills that will make a real difference to everyday practice and delivers the latest relevant, practical, and implementable clinical updates and medical innovations from a vast network of local suppliers.
Kevin Scrimshaw, Commercial Director, ANZ and Martina Clark Territory Business Manager, VIC Australia from the DermaSensor team will present the DermaSensor device, an easy-to-use, handheld device that uses world-first technology to augment clinician decision making by providing accurate differentiation between malignant and benign skin lesions. A recent clinical study found that DermaSensor achieved a sensitivity of 100 percent for detecting melanoma and 94 percent for detecting nonmelanoma skin cancer.
“It will be exciting to demonstrate how DermaSensor’s technology can help clinicians quickly and effectively check for skin cancer,” explains Kevin.
This world leading breakthrough was achieved using Elastic Scattering Spectroscopy. The technology was pioneered at Boston University and University College London. It uses light to evaluate cellular and subcellular structures of the skin.
DermaSensor has spent the past three years miniaturising its spectroscopy technology into an easy-to-use handheld device. A physician gently touches the non-invasive device tip to a selected mole and a spectral sensor records how dozens of wavelengths of light reflect off cells beneath the surface of the skin. The company’s proprietary algorithm instantly analyses the reflected photons as “Higher Risk” or “Lower Risk” to support a physician’s referral decision. It complements the physician’s skill and experience by using the power of machine learning to support clinical evaluation.
Its speed and ease of use improves workflow by extending lesion identification and evaluation to trained team members. Patients can expect to experience fewer unnecessary complications or side effects and it allows medical practitioners to spend less time on lengthy procedures.
The device is undergoing FDA and TGA approval and is expected to be available in Australia in late-2020. The DermaSensor device is low-cost and easy-to-use. It enables healthcare providers and patients to receive fast and accurate skin lesion assessments to ultimately improve outcomes for patients with skin cancer.
